LENEXA, Kan., Feb. 13, 2025 — In alignment with our commitment to expand access to innovative veterinary cancer care across the country, ELIAS Animal Health is excited to announce that the Canine Transplant and Apheresis Center (CTAC) in Chattanooga, Tennessee is now providing apheresis services to veterinary patients undergoing the ELIAS Cancer Immunotherapy (ECI®). CTAC is located inside the Pullen Cancer Center at VCSG.
ECI® is an adoptive cell therapy that harnesses the dog’s own immune system to identify and attack cancer cells. Apheresis is a critical step in the ECI® treatment protocol, which is a one-time procedure used to collect primed immune cells for activation and expansion. This new partnership enables broader access for veterinarians and pet owners interested in pursuing ECI® to treat cancer in dogs in the southeast region of the United States.
Questions about treatment and patient referrals should be directed to ELIAS Animal Health. The decision to pursue ECI® must be made prior to surgery so that cancer tissue can be collected to manufacture vaccines.
A complete list of veterinary hospitals offering ECI® can be found on our website.
About CTAC
The Canine Transplant and Apheresis Center (CTAC) is a leading-edge veterinary facility and one of only two centers worldwide offering hematopoietic stem cell transplants (HSCT) for dogs. HSCT is a curative option for dogs with blood cancers, such as lymphoma and leukemia, as well as certain non-cancerous bone marrow disorders. CTAC also offers therapeutic plasma exchange for managing immune-mediated diseases and toxicities, along with mononuclear cell collections to support adoptive cell therapy. For more information, visit www.thectac-usa.com.
About ELIAS Animal Health
ELIAS Animal Health is a medical biotechnology company advancing novel targeted T cell-based and oncolytic immunotherapies for the treatment of canine cancers. The ELIAS Cancer Immunotherapy (ECI®), a first-in-class adoptive cell therapy for the treatment of canine cancer, is available to veterinarians commercially under 9 CFR 103.3 as an experimental autologous prescription product. The company’s novel therapeutic approach offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Learn more at www.eliasanimalhealth.com.